Ombitasvir/paritaprevir/ritonavir plus ribavirin for 24 weeks in patients with HCV GT4 and compensated cirrhosis (AGATE-I Part II).

Tarik AsselahNegar Niki AlamiChristophe MorenoStanislas PolStylianos KaratapanisMichael GschwantlerYves HorsmansIoannis ElefsiniotisDominique LarreyCarlo FerrariMario RizzettoAlessandra OrlandiniJose Luis CallejaSavino BrunoGretja SchnellRoula QaqishRebecca RedmanTami Pilot-MatiasSarah Kopecky-BrombergYao YuNiloufar Mobashery

Published in: Health science reports (2019)

AGATE-I Part II indicates that extending treatment beyond 12 weeks in genotype 4-infected patients with compensated cirrhosis does not offer additional benefit.

Keyphrases

hepatitis c virus
gestational age
human immunodeficiency virus
antiretroviral therapy
combination therapy
replacement therapy